Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (81-90 of 264) with videos related to

Pageof 27
Sort By:
Breast (Edinburgh, Scotland)|August 16, 2020
Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapyEmilia Montagna, Giuseppe Cancello, Eleonora Pagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancerSilvia Dellapasqua, Francesco Bertolini, Vincenzo Bagnardi, et al.
European Journal of Cancer (Oxford, England : 1990)|October 13, 2007
Unnecessary axillary node dissections in the sentinel lymph node eraMattia Intra, Nicole Rotmensz, Denise Mattar, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Local therapy for breast cancer in malignant lymphoma survivorsMattia Intra, Denise Mattar, Claudia Sangalli, et al.
Breast Cancer Research and Treatment|January 10, 2012
Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patientsCaterina Fumagalli, Giancarlo Pruneri, Paola Possanzini, et al.
The Lancet. Oncology|January 13, 2018
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 studyLuca Gianni, Giancarlo Bisagni, Marco Colleoni, et al.
Breast (Edinburgh, Scotland)|November 5, 2016
Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety studyAntonio Toesca, Nickolas Peradze, Andrea Manconi, et al.
Ebiomedicine|March 9, 2019
Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive studySalvatore Pece, Davide Disalvatore, Daniela Tosoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus BevacizumabAngelica Calleri, Anna Bono, Vincenzo Bagnardi, et al.
NPJ Breast Cancer|January 11, 2022
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancerLuca Gianni, Marco Colleoni, Giancarlo Bisagni, et al.
Pageof 27

Showing results (81-90 of 264) with videos related to

Sort By:
Pageof 27
Breast (Edinburgh, Scotland)|August 16, 2020
Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapyEmilia Montagna, Giuseppe Cancello, Eleonora Pagan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 17, 2008
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancerSilvia Dellapasqua, Francesco Bertolini, Vincenzo Bagnardi, et al.
European Journal of Cancer (Oxford, England : 1990)|October 13, 2007
Unnecessary axillary node dissections in the sentinel lymph node eraMattia Intra, Nicole Rotmensz, Denise Mattar, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Local therapy for breast cancer in malignant lymphoma survivorsMattia Intra, Denise Mattar, Claudia Sangalli, et al.
Breast Cancer Research and Treatment|January 10, 2012
Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patientsCaterina Fumagalli, Giancarlo Pruneri, Paola Possanzini, et al.
The Lancet. Oncology|January 13, 2018
Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 studyLuca Gianni, Giancarlo Bisagni, Marco Colleoni, et al.
Breast (Edinburgh, Scotland)|November 5, 2016
Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety studyAntonio Toesca, Nickolas Peradze, Andrea Manconi, et al.
Ebiomedicine|March 9, 2019
Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive studySalvatore Pece, Davide Disalvatore, Daniela Tosoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 10, 2009
Predictive Potential of Angiogenic Growth Factors and Circulating Endothelial Cells in Breast Cancer Patients Receiving Metronomic Chemotherapy Plus BevacizumabAngelica Calleri, Anna Bono, Vincenzo Bagnardi, et al.
NPJ Breast Cancer|January 11, 2022
Effects of neoadjuvant trastuzumab, pertuzumab and palbociclib on Ki67 in HER2 and ER-positive breast cancerLuca Gianni, Marco Colleoni, Giancarlo Bisagni, et al.
Pageof 27